Harte Hanks Posts $7.1M Nine-Month Loss as Merger Costs Bite; Cash Falls to $2.4M
HHS has more than doubled off its 52-week low of $2 on light trading volume (0.1× avg).
Summary
Harte Hanks' Q3 10-Q shows a $7.1 million nine-month loss, $8.7 million of operating cash burn and cash down to $2.4 million, with $6.3 million drawn on its credit line. The $5.00-per-share Star Equity merger remains on its previously announced terms, still targeted to close before the end of 2026.
Key Events · Earnings and Guidance · HHS
-
Nine-Month Loss Widens to $7.1M
Net loss was $7.1 million ($0.96 per share) for the nine months ended September 30, 2026, versus $3.0 million ($0.41) a year earlier; Q3 alone lost $1.5 million ($0.20) against $2.3 million ($0.31) in Q3 2025.
-
Operating Cash Burn Reaches $8.7M
Net cash used in operating activities was $8.7 million for the nine months, versus $2.5 million in the prior-year period, driven by the larger net loss and a $4.7 million receivables build.
-
Cash Falls to $2.4M, Revolver Drawn $6.3M
Cash and restricted cash ended at $2.4 million versus $5.6 million at December 31, 2025, with $6.3 million borrowed under the $25.0 million Texas Capital facility and $13.8 million of remaining availability.
-
Merger Costs Lift SG&A 47%
Advertising, selling, general and administrative expense rose to $7.6 million in Q3 from $5.1 million, primarily on higher professional service and legal expenses related to the pending acquisition.
Analysis · HHS · Trade & Services
The merger with Star Equity at $5.00 per share is already public and unchanged, so the deal math is not the story here. What is new is the deterioration underneath it: a $7.1 million nine-month net loss versus $3.0 million a year ago, $8.7 million of operating cash burn, and cash down to $2.4 million with $6.3 million now drawn on the revolver. SG&A jumped 47.1% in the quarter on professional and legal fees tied to the pending deal. Management says liquidity is adequate for the next twelve months, but the cushion is now the $13.8 million of remaining revolver capacity, not cash on hand. If the merger slips past year-end, the standalone company has very little room.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HHS was trading at $4.03 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $30M. The 52-week trading range was $2.00 to $4.67. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.